Covid-19 - Medical / Health Care

SFA Therapeutics novel immunomodualtor, SFA006 is planned for testing in COVID-19 Patients 4th Quarter 2020. The trial will test the compound’s ability to prevent the onset of Cytokine Storm Syndrome (CSS) and progression to Acute Respiratory Distress Syndrome (ARDS) in COVID-19 positive patients. Patients will be dosed and monitored for symptom progression hospitalization and death.